#107 $QURE uniQure Gene Therapy Breakthrough or Regulatory Reversal

In this episode of Sue Wall Street Holding Wall Street Accountable, we break down the securities class action involving $QURE uniQure and its AMT 130 gene therapy for Huntington disease. We examine the seventy five percent slowing claim, the Phase One Phase Two trial using an external control from ENROLL HD, the Biologics License Application timeline, the FDA reversal on study alignment, the three hundred forty five million dollar stock offering, and the forty nine percent stock drop. This deep dive is for biotech investors, healthcare traders, and anyone following gene therapy stocks, FDA approvals, clinical trial risk, and securities litigation news. Visit ZLK.com for more info. Add our WhatsApp Channel. We’re not lawyers or accountants, so don’t take this as legal or financial advice.